In particular, several TKIs exhibiting their activities against different kinase types have also been shown to impair DNA damage repair (DDR) pathways, inhibit the pro-survival signaling, target cancer stem cells (CSCs), normalize the tumor microenvironment (TME), and inhibit efflux pump function by acting directly on ABC transporters [144,145]. The gene discussed is ABCG2; the disease is cancer.